PC23546C

Terminal Disclaimer Submitted in Response to Restriction Requirement and Terminal Disclaimers



Certificate of Mailing (37 C.F.R. §1.8):

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Mail Stop: Amendment, Commissioner for Patents,

PO Box 1450, Alexandria, VA 22313-1450 on this 21st day of March 2006.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

MALCOLM WILSON MOON, ET AL.

Serial No.: 10/774,415

Filed: February 10, 2004

For: PRODRUGS OF 3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE

DERIVATIVES

Group Art Unit: 1626

Examiner: Kamal A. Saeed

Confirmation No. 9923

Attorney Docket No.: PC23546C

Mail Stop: Amendment **Commissioner For Patents** P.O. Box 1450

Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith are the following documents:

1. Amendments and Response

2. Terminal Disclaimer over US Patent No. 6,716,870

3. Terminal Disclaimer over US Patent No. 6,482,848

4. Fee Transmittal + duplicate

5. Return Postcard

6. Total Fee Due (\$260.00)

12 pages;

1 page;

1 page;

1 page + duplicate;

1 postcard; and

Deposit Account.

Respectfully submitted,

Date: _ Mar. 21, 200

Ye Hua

Attorney For Applicants Registration No. 53,042

Agouron Pharmaceuticals, Inc./A Pfizer Company Patent Department 10777 Science Center Drive San Diego, California 92121 Phone: (858) 622-3020

Fax: (858) 678-8233

Approved for use through 07/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

work Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number Complete if Known Effective on 12/08/2004. fánt to the Consolidated Appropriations Act, 2005 (H.R. 4818). 10/774,415 Application Number TRANSMIT February 10, 2004 Filing Date For FY 2005 First Named Inventor Malcolm Wilson Moon **Examiner Name** Kamal A. Saeed Applicant claims small entity status. See 37 CFR 1.27 Art Unit 1626 PC23546C TOTAL AMOUNT OF PAYMENT 260.00 Attorney Docket No. METHOD OF PAYMENT (check all that apply) None Check Credit Card Money Order Other (please identify): Deposit Account Name: Agouron Pharmaceuticals ✓ Deposit Account Deposit Account Number: 500329 For the above-identified deposit account, the Director is hereby authorized to: (check all that apply) Charge fee(s) indicated below, except for the filing fee Charge fee(s) indicated below Charge any additional fee(s) or underpayments of fee(s) ✓ Credit any overpayments under 37 CFR 1.16 and 1.17 WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. **FEE CALCULATION** 1. BASIC FILING, SEARCH, AND EXAMINATION FEES **EXAMINATION FEES FILING FEES** SEARCH FEES **Small Entity Small Entity Small Entity** Fees Paid (\$) Fee (\$) Fee (\$) Fee (\$) Fee (\$) **Application Type** Fee (\$) Fee (\$) 500 250 200 100 300 150 Utility 200 100 100 50 130 65 Design 160 80 200 300 150 100 Plant 600 300 500 250 300 150 Reissue 0 0 200 0 0 Provisional 100 **Small Entity** 2. EXCESS CLAIM FEES Fee (\$) Fee (\$) Fee Description 50 Each claim over 20 (including Reissues) 100 200 Each independent claim over 3 (including Reissues) 180 360

Multiple dependent	claims			200	100
Total Claims	Extra Claims	Fee (\$) Fee Paid (\$)		Multiple Dependent Claims	
- 20 or HP =			=	<u>Fee (\$)</u>	Fee Paid (\$)
HP = highest number of to		•			
Indep. Claims	Extra Claims	Fee (\$)	Fee Paid (\$)		
3 or HP =			=		
HP = highest number of inc	dependent claims paid f	or, if greater tha	ın 3.		

THE - Highest Humber of independent define pare 181, it greater

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 cm. of the control of

sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets Extra Sheets Number of each additional 50 or fraction thereof (round up to a whole number) x

Fee (\$)

Fee Paid (\$)

Fees Paid (\$)

4. OTHER FEE(S)
Non-English Specification, \$130 fee (no small entity discount)

Other (e.g., late filing surcharge): Statutory Disclaimer (Fee Code 1814/2814 37 C.F.R. 1.20(d))

\$260.00

SUBMITTED BY	. 1		
Signature	Voltus	Registration No. (Attorney/Agent) 53,042	Telephone 858-622-3020
Name (Print/Type) Ye H	lua	(),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Date March 21, 2006

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.